{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:24:34Z","timestamp":1787840674269,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>\n                    Non-alcoholic fatty liver disease (NAFLD), a major cause of chronic liver disease, is known to affect a quarter of the global adults. Natural history of NAFLD shows interindividual variation, traditionally it progresses from simple steatosis to steatohepatitis to fibrosis\/cirrhosis and finally yet rarely to hepatocellular carcinoma. It is largely a lifestyle-related disease and is often labeled as the hepatic manifestation of metabolic syndrome. Both prevention and control of NAFLD include controlling risk factors (obesity, diabetes mellitus, hypertension and dyslipidemia), through lifestyle modification and medications. Drug therapy for NAFLD\n                    <jats:italic toggle=\"yes\">per se<\/jats:italic>\n                    is still evolving and till date, no drugs are approved. It is clinically silent, especially in the early stages, and is a diagnosis of exclusion. Certain easily calculated indices can stratify cases into high or low risk for advanced fibrosis, thereby dictating appropriate monitoring and treatment measures. In addition to complications specific to liver disease in those who do progress to advanced fibrosis or cirrhosis, an increased risk of nonliver disease-related morbidity and mortality is also present. Challenges are manifold and include rising burden due to ever-growing epidemic of diabetes and obesity, low public awareness, fragmented healthcare, no approved drugs, and dearth of data on magnitude and epidemiology of the disease. The recent integration of NAFLD into the National Program for Prevention and Control of Non-Communicable Diseases (NPCDCS) by the Ministry of Health and Family Welfare of India is a welcome step in this direction as the contributory factors are mostly the same for all diseases and controlling any one or all of them will have a desired impact on the prevalence of all the diseases under this program.\n                  <\/jats:p>","DOI":"10.4103\/ijcm.ijcm_174_24","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T04:02:45Z","timestamp":1729137765000},"page":"780-785","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Non-alcohlic Fatty Liver Disease (NAFLD): Is it a Dormant Volcano or Tip of an Iceberg?"],"prefix":"10.4103","volume":"49","author":[{"given":"Prashasti","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of General Medicine, Lady Hardinge Medical College, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"issue":"Suppl 6","key":"R1-20241030","doi-asserted-by":"crossref","first-page":"s77","DOI":"10.7861\/clinmedicine.15-6-s77","article-title":"An overview of the genetics, mechanisms and management of NAFLD and ALD","volume":"15","author":"Rowell","year":"2015","journal-title":"Clin Med (Lond)"},{"key":"R2-20241030","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4103\/ijcm.ijcm_900_21","article-title":"Non-alcoholic fatty liver disease: Role of medical colleges in its prevention and control","volume":"47","author":"Nath","year":"2022","journal-title":"Indian J Community Med"},{"key":"R4-20241030","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"R5-20241030","article-title":"Accessed at New MASLD Nomenclature | AASLD"},{"key":"R6-20241030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"R7-20241030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jceh.2021.11.010","article-title":"Prevalence of non-alcoholic fatty liver disease in India: A systematic review and meta-analysis","volume":"12","author":"Shalimar,","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"R8-20241030","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors","volume":"18","author":"Juanola","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"R9-20241030","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: The state of the disease","volume":"58","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"R10-20241030","doi-asserted-by":"crossref","first-page":"e9302","DOI":"10.15252\/emmm.201809302","article-title":"The role of the microbiome in NAFLD and NASH","volume":"11","author":"Kolodziejczyk","year":"2019","journal-title":"EMBO Mol Med"},{"key":"R11-20241030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"R12-20241030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0019-557X.177295","article-title":"Prevalence of non-alcoholic fatty liver disease in an adult population in a rural community of Haryana, India","volume":"60","author":"Majumdar","year":"2016","journal-title":"Indian J Publ Health"},{"key":"R13-20241030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/flgastro-2013-100403","article-title":"Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging","volume":"5","author":"Dyson","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"R14-20241030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"R15-20241030","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4103\/ijcm.ijcm_1213_21","article-title":"Anthropometric indices and type 2 diabetes mellitus as a risk factor in predicting nonalcoholic fatty liver disease \u2013 A prospective study in Indian population","volume":"47","author":"Suvarna","year":"2022","journal-title":"Indian J Community Med"},{"key":"R16-20241030","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"R17-20241030","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R18-20241030","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.3748\/wjg.v23.i36.6571","article-title":"Nonalcoholic fatty liver disease: Evolving paradigms","volume":"23","author":"Lonardo","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R19-20241030","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"R20-20241030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A Meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"R21-20241030","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Community Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijcm.ijcm_174_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:26:55Z","timestamp":1787837215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijcm.ijcm_174_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijcm.ijcm_174_24","relation":{},"ISSN":["0970-0218","1998-3581"],"issn-type":[{"value":"0970-0218","type":"print"},{"value":"1998-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"2024-03-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}